Clinical Trials
9 trialsNCT02965716 2026-05-20
Talimogene Laherparepvec and Pembrolizumab in Treating Patients With Stage III-IV Melanoma
National Cancer Institute (NCI)
Phase 2 Active not recruiting
NCT02923778 2026-05-13
Talimogene Laherparepvec and Radiation Therapy in Treating Patients With Newly Diagnosed Soft Tissue Sarcoma That Can Be Removed by Surgery
National Cancer Institute (NCI)
Phase 2 Active not recruiting
NCT02978625 2026-05-13
Talimogene Laherparepvec and Nivolumab in Treating Patients With Refractory Lymphomas or Advanced or Refractory Non-melanoma Skin Cancers
National Cancer Institute (NCI)
Phase 2 Active not recruiting
NCT07102394 2026-05-08
Feasibility and Tolerability of IMLYGIC for the Treatment of Cutaneous Neurofibromas in Adults With NF1
Johns Hopkins University
Phase 1 Recruiting
NCT02779855 2026-03-10
Talimogene Laherparepvec in Combination With Neoadjuvant Chemotherapy in Triple Negative Breast Cancer
H. Lee Moffitt Cancer Center and Research Institute
Phase 1/2 Completed
NCT04599062 2026-01-29
TVEC and Preop Radiation for Sarcoma (8 ml Dose)
University of Iowa
Phase 1/2 Active not recruiting
NCT06660810 2026-01-15
Neoadjuvant Intralesional Injection of Talimogene Laherparepvec
University of Iowa
Phase 2 Active not recruiting
NCT03069378 2025-10-29
A Study of Talimogene Laherparepvec (T-VEC) in Combination With Pembrolizumab in Patients With Metastatic and/or Locally Advanced Sarcoma
Memorial Sloan Kettering Cancer Center
Phase 2 Active not recruiting
NCT03802604 2025-09-09
PROMETEO
SOLTI Breast Cancer Research Group
Phase EARLY_PHASE1 Completed